Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 2,886 shares of the company's stock in a transaction on Monday, April 7th. The stock was sold at an average price of $35.78, for a total value of $103,261.08. Following the completion of the sale, the executive vice president now owns 64,689 shares of the company's stock, valued at $2,314,572.42. This represents a 4.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Andrew Callos also recently made the following trade(s):
- On Monday, March 17th, Andrew Callos sold 2,775 shares of Cytokinetics stock. The shares were sold at an average price of $44.38, for a total value of $123,154.50.
- On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The shares were sold at an average price of $45.00, for a total transaction of $4,500.00.
- On Thursday, March 6th, Andrew Callos sold 3,341 shares of Cytokinetics stock. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07.
Cytokinetics Trading Down 3.9 %
Cytokinetics stock opened at $34.57 on Wednesday. Cytokinetics, Incorporated has a 52 week low of $33.59 and a 52 week high of $75.71. The stock has a 50-day moving average price of $44.09 and a 200 day moving average price of $48.56. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The company has a market capitalization of $4.09 billion, a price-to-earnings ratio of -6.43 and a beta of 0.94.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts' expectations of $14.26 million. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.
Hedge Funds Weigh In On Cytokinetics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Harvey Capital Management Inc. acquired a new stake in Cytokinetics during the fourth quarter worth about $1,040,000. abrdn plc boosted its position in Cytokinetics by 29.4% in the 4th quarter. abrdn plc now owns 450,513 shares of the biopharmaceutical company's stock worth $21,192,000 after purchasing an additional 102,457 shares in the last quarter. AlphaQuest LLC grew its stake in shares of Cytokinetics by 113,500.0% during the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,135 shares during the period. Vanguard Group Inc. increased its holdings in shares of Cytokinetics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company's stock valued at $560,520,000 after purchasing an additional 154,216 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Cytokinetics by 1.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company's stock valued at $62,807,000 after buying an additional 13,798 shares during the period.
Analyst Ratings Changes
A number of equities analysts recently commented on CYTK shares. Evercore ISI raised shares of Cytokinetics to a "strong-buy" rating in a research note on Friday, February 7th. Citigroup initiated coverage on Cytokinetics in a research note on Friday, February 7th. They set a "buy" rating and a $86.00 price objective for the company. JMP Securities reiterated a "market outperform" rating and issued a $78.00 target price on shares of Cytokinetics in a research note on Friday, February 7th. Royal Bank of Canada increased their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Cytokinetics presently has an average rating of "Moderate Buy" and a consensus target price of $82.00.
View Our Latest Report on CYTK
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
